Drug Trial Radar · NCT04460352
Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer
Last checked: Nov 19, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,020
Planned (sponsor's estimate)
Start
Nov 27, 2020
Primary completion
Dec 31, 2026
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- Karolinska University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Leipzig; The Swedish Research Council
- First posted
- Jul 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NEEDS is a pragmatic open-label, randomised, controlled, phase III, multicenter trial with non-inferiority design with regard to the first co-primary endpoint overall survival and superiority for the experimental intervention definitive chemoradiotherapy. A second co-primary endpoint is global health related quality of life (HRQOL) one year after randomisation. A third co-primary endpoint is eating restictions one year after randomisation. The aim is to compare outcomes after neoadjuvant chemoradiotherapy with subsequent esophagectomy to definitive chemoradiotherapy with surveillance and salvage esophagectomy as needed in patients with resectable locally advanced squamous cell carcinoma (SCC) of the esophagus, with the aim to provide generalisable guidance for future clinical practice.
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
Neoadjuvant radiotherapy (arm A)Radiation
1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.
Carboplatin, paclitaxelDrug
Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy
EsophagectomyProcedure
Esophagectomy performed within 8 weeks after termination of chemoradiotherapy
Neoadjuvant radiotherapy (arm B)Radiation
Two alternative schemes: 1. 1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy. 2. 2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy.
Carboplatin, paclitaxelDrug
Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).
Cisplatin, paclitaxelDrug
Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.
Oxaliplatin, calcium folinate, 5-fluorouracilDrug
FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.
EsophagectomyProcedure
Esophagectomy only in case of residual or recurrent locoregional cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: 3 years after randomisation
- Global Health-related quality of life (HRQOL)Time frame: 1 year after randomisation
- Eating restrictionsTime frame: 1 year after randomisation
Locations
12 sites in 5 countries. Site status is shown where the registry gives one.
McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
Cancer Clinical Trials Unit (CCTU) at St. James's Hospital
Dublin, Dublin, Ireland · Recruiting
Oslo universitetssykehus
Oslo, Norway · Recruiting
Universitetssykehuset Nord-Norge
Tromsø, Norway · Recruiting
St Olavs Hospital
Trondheim, Norway · Recruiting
Linköpings universitetssjukhus
Linköping, Sweden · Recruiting
Skånes universitetssjukhus
Lund, Sweden · Recruiting
Örebro universitetssjukhus
Örebro, Sweden · Recruiting
Karolinska University Hospital
Stockholm, Sweden · Recruiting
Norrlands universitetssjukhus
Umeå, Sweden · Recruiting
Akademiska sjukhuset
Uppsala, Sweden · Recruiting
Chang Gung Memorial Hospital
Linkou District, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.